pioglitazone has been researched along with Cruveilhier-Baumgarten Syndrome in 2 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Cruveilhier-Baumgarten Syndrome: Liver cirrhosis with intrahepatic portal obstruction, HYPERTENSION, and patent UMBILICAL VEINS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone treatment decreases portosystemic shunting via modulation of splanchnic inflammation and neoangiogenesis." | 7.80 | Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. ( Angermayr, B; Boucher, Y; Fuhrmann, V; Grahovac, J; Horvatits, T; Klein, S; Mitterhauser, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Stift, J; Trauner, M; Trebicka, J, 2014) |
| "Pioglitazone treatment decreases portosystemic shunting via modulation of splanchnic inflammation and neoangiogenesis." | 3.80 | Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. ( Angermayr, B; Boucher, Y; Fuhrmann, V; Grahovac, J; Horvatits, T; Klein, S; Mitterhauser, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Stift, J; Trauner, M; Trebicka, J, 2014) |
| "Berardinelli- Seip syndrome is an autosomal recessive disorder characterized by generalized lipoatrophy, extreme insulin resistance with dyslipidemia in childhood and development of diabetes in adolescence." | 1.38 | An unusual cause of delayed puberty: Berardinelli- Seip syndrome. ( Dhull, P; Kumar, KV; Patnaik, SK; Upreti, V, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Upreti, V | 1 |
| Dhull, P | 1 |
| Patnaik, SK | 1 |
| Kumar, KV | 1 |
| Schwabl, P | 1 |
| Payer, BA | 1 |
| Grahovac, J | 1 |
| Klein, S | 1 |
| Horvatits, T | 1 |
| Mitterhauser, M | 1 |
| Stift, J | 1 |
| Boucher, Y | 1 |
| Trebicka, J | 1 |
| Trauner, M | 1 |
| Angermayr, B | 1 |
| Fuhrmann, V | 1 |
| Reiberger, T | 1 |
| Peck-Radosavljevic, M | 1 |
2 other studies available for pioglitazone and Cruveilhier-Baumgarten Syndrome
| Article | Year |
|---|---|
An unusual cause of delayed puberty: Berardinelli- Seip syndrome.
Topics: Administration, Cutaneous; Adolescent; Atorvastatin; Combined Modality Therapy; Diet, Fat-Restricted | 2012 |
Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats.
Topics: Animals; Cell Movement; Disease Models, Animal; Hemodynamics; Human Umbilical Vein Endothelial Cells | 2014 |